SANUWAVE reports record Q4 revenue $7.0M (+27% YoY), positive operating income, guides FY2024 50% growth

SANUWAVE Health, Inc.

Q4 2023 revenue record $7.0M (+27% vs Q4 2022 $5.5M); operating income $1.0M vs loss $1.5M.
FY2023 revenue $20.4M (+22% from $16.7M); adjusted EBITDA loss $1.2M vs $7.2M, improvement of $6.0M.
UltraMist systems: 211 sold in FY2023; Q4 consumables revenue $3.6M (+21% YoY).
Guidance: Q1 2024 revenue +45-55% vs Q1 2023; FY2024 revenue growth 50% vs FY2023.
Net income Q4 $18.2M (non-cash derivative fair value change); FY2023 net loss $25.8M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SANUWAVE Health, Inc. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $7.0 million, net income $18.2 million. Guidance initiated.

Period: the fourth quarter and fiscal year ended December 31, 2023
Revenue: $7.0 million
Net income: $18.2 million
Guidance: initiated
Result: reported results

Exact text from the filing

SANUWAVE Announces Record Q4 and FY2023 Revenue Q4 2023 revenues were a record $7.0 million, up 27% from Q4 2022 FY 2023 revenues were a record $20.4 million, up 22% from FY2022 Operating income was $1 million for Q4 2023 compared to an operating loss of $1.5 million for Q4 2022 Company provides guidance for revenue growth of 45-55% for Q1 2024 vs Q1 2023 and initiates annual guidance for FY2024 of 50% revenue growth vs. FY2023

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

SANUWAVE Health, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-014708

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.